Skip to content

Main Navigation

  • About us
    • Our team
    • Employee stories
    • Working with us
    • Our principles
    • Mission, vision & values
    • History
    • Corporate Social Responsibility
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK/PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
    • Publications
    • Case studies
    • Academic collaborations
  • Careers
  • Events
  • News
  • Contact us
  • LinkedIn

Bimekizumab population pharmacokinetic and exposure-response analyses in adults with moderate to severe hidradenitis suppurativa

ACoP15 (Nov 2024), Poster: T-041
Jönsson S, Gallais F, Janssen JM, Rolleri R, Khandelwal A, Dua P, Sidhu J.
ConferenceInflammationPharmacometricsProgram strategies and efficiencies

Pharmetheus Affiliates

Portrait-of-Siv-Jonsson-Pharmetheus
Senior Consultant

Siv Jönsson

See bio
Portrait-of-Fanny-Gallais-Pharmetheus
Consultant

Fanny Gallais

See bio
Portrait-of-Julie-Janssen_Pharmetheus-1
Consultant

Julie Janssen

See bio
Portrait-of-Viviana-Moroso-Pharmetheus
Quality Control and Medical Writer

Viviana Moroso

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

info@pharmetheus.com

+46(0)18-51 33 28

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.